Financial PerformanceFME25 savings are running ahead of plan and expect €205m for the full year, which supports sequential margin improvement.
Market PositionThe company is the only one with FDA-approved technology for high-volume hemodiafiltration, positioning it advantageously in the market.
Technology And InnovationThe introduction of new technology, such as the 5008X machine, is expected to support clinic utilization and improve patient care, which can enhance operational efficiency.